ATX inhibitor 5
Modify Date: 2025-08-27 14:55:41
ATX inhibitor 5 structure
|
Common Name | ATX inhibitor 5 | ||
|---|---|---|---|---|
| CAS Number | 2402772-45-4 | Molecular Weight | 474.87 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H18ClF3N6O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ATX inhibitor 5ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 has anti-hepatofibrosis effect, and reduces CCl4-induced hepatic fibrosis level prominently[1]. |
| Name | ATX inhibitor 5 |
|---|
| Description | ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 has anti-hepatofibrosis effect, and reduces CCl4-induced hepatic fibrosis level prominently[1]. |
|---|---|
| Related Catalog | |
| Target |
Autotaxin |
| In Vitro | ATX inhibitor 5 displays anti-proliferative activities with IC50s of 1.21 and 0.78 µM, respectively[1]. Cell Proliferation Assay[1] Cell Line: CFs and t-HSC/Cl-6 cells Concentration: 0.0001, 0.01, 1, 100, 10000 µM Incubation Time: 48 hours Result: Displayed activities against CFs and t-HSC/Cl-6 cells with IC50s of 1.21 and 0.78 µM, respectively. |
| In Vivo | ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently[1]. Animal Model: Male Konmin mice (8-week old, 22-25 g)[1] Dosage: 20, 40 mg/kg Administration: Orally; once daily for two weeks Result: Prominently reduced CCl4-induced hepatic fibrosis level. |
| References |
| Molecular Formula | C22H18ClF3N6O |
|---|---|
| Molecular Weight | 474.87 |
| InChIKey | VHRNHTUEITYZIH-VPUKRXIYSA-N |
| SMILES | O=C(NN=Cc1ccc(Cl)cc1)N1CCc2ncnc(Nc3cccc(C(F)(F)F)c3)c2C1 |